Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman : results from four successive nationwide sero-epidemiological surveys
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved..
OBJECTIVE: To assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Oman and longitudinal changes in antibody levels over time within the first 11 months of the coronavirus disease 2019 (COVID-19) pandemic.
METHODS: This nationwide cross-sectional study was conducted as a four-cycle serosurvey using a multi-stage stratified sampling method from July to November 2020. A questionnaire was used and included demographics, history of acute respiratory infection and list of symptoms, COVID-19 contact, previous diagnosis or admission, travel history and risk factors.
RESULTS: In total, 17,457 participants were surveyed. Thirty percent were female and 66.3% were Omani. There was a significant increase in seroprevalence throughout the study cycles, from 5.5% (4.8-6.2%) in Cycle 1 to 22% (19.6-24.6%) in Cycle 4. There was no difference in seroprevalence between genders, but significant differences were found between age groups. There was a transition of seroprevalence from being higher in non-Omanis than Omanis in Cycle 1 [9.1% (7.6-10.9%) vs 3.2% (2.6-3.9%)] to being higher in Omanis than non-Omanis in Cycle 4 [24.3% (21.0-27.9%) vs 16.8% (14.9-18.9%)]. There was remarkable variation in the seroprevalence of SARS-CoV-2 according to governorate. Close contacts of people with COVID-19 had a 96% higher risk of having the disease [adjusted odds ratio (AOR) 1.96, 95% confidence intervals (CI) 1.64-2.34]. Labourers had 58% higher risk of infection compared with office workers (AOR 1.58, 95% CI 1.04-2.35).
CONCLUSION: This study showed a wide variation in the spread of SARS-CoV-2 across governorates in Oman, with higher estimated seroprevalence in migrants in the first two cycles. Prevalence estimates remain low and are insufficient to provide herd immunity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 112(2021) vom: 03. Nov., Seite 269-277 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 03.12.2021 Date Revised 21.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2021.09.062 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331424533 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331424533 | ||
| 003 | DE-627 | ||
| 005 | 20231225213431.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2021.09.062 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1104.xml |
| 035 | |a (DE-627)NLM331424533 | ||
| 035 | |a (NLM)34601146 | ||
| 035 | |a (PII)S1201-9712(21)00770-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Al-Abri, Seif Salem |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman |b results from four successive nationwide sero-epidemiological surveys |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.12.2021 | ||
| 500 | |a Date Revised 21.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVE: To assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Oman and longitudinal changes in antibody levels over time within the first 11 months of the coronavirus disease 2019 (COVID-19) pandemic | ||
| 520 | |a METHODS: This nationwide cross-sectional study was conducted as a four-cycle serosurvey using a multi-stage stratified sampling method from July to November 2020. A questionnaire was used and included demographics, history of acute respiratory infection and list of symptoms, COVID-19 contact, previous diagnosis or admission, travel history and risk factors | ||
| 520 | |a RESULTS: In total, 17,457 participants were surveyed. Thirty percent were female and 66.3% were Omani. There was a significant increase in seroprevalence throughout the study cycles, from 5.5% (4.8-6.2%) in Cycle 1 to 22% (19.6-24.6%) in Cycle 4. There was no difference in seroprevalence between genders, but significant differences were found between age groups. There was a transition of seroprevalence from being higher in non-Omanis than Omanis in Cycle 1 [9.1% (7.6-10.9%) vs 3.2% (2.6-3.9%)] to being higher in Omanis than non-Omanis in Cycle 4 [24.3% (21.0-27.9%) vs 16.8% (14.9-18.9%)]. There was remarkable variation in the seroprevalence of SARS-CoV-2 according to governorate. Close contacts of people with COVID-19 had a 96% higher risk of having the disease [adjusted odds ratio (AOR) 1.96, 95% confidence intervals (CI) 1.64-2.34]. Labourers had 58% higher risk of infection compared with office workers (AOR 1.58, 95% CI 1.04-2.35) | ||
| 520 | |a CONCLUSION: This study showed a wide variation in the spread of SARS-CoV-2 across governorates in Oman, with higher estimated seroprevalence in migrants in the first two cycles. Prevalence estimates remain low and are insufficient to provide herd immunity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antibody seroprevalence | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Herd immunity | |
| 650 | 4 | |a Oman | |
| 650 | 4 | |a Prevalence | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Sero-epidemiological surveys | |
| 650 | 4 | |a Serosurvey | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Al-Wahaibi, Adil |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Kindi, Hanan |e verfasserin |4 aut | |
| 700 | 1 | |a Kurup, Padmamohan J |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Maqbali, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Mayahi, Zayid |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Tobi, Mohammed Hamed |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Katheri, Salim Habbash |e verfasserin |4 aut | |
| 700 | 1 | |a Albusaidi, Sultan |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Sukaiti, Mahmood Humaid |e verfasserin |4 aut | |
| 700 | 1 | |a Al Balushi, Ahmed Yar Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelgadir, Iyad Omer |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Shehi, Nawal |e verfasserin |4 aut | |
| 700 | 1 | |a Morkos, Essam |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Maani, Amal |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Rawahi, Bader |e verfasserin |4 aut | |
| 700 | 1 | |a Alyaquobi, Fatma |e verfasserin |4 aut | |
| 700 | 1 | |a Alqayoudhi, Abdullah |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Harthy, Khalid |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Khalili, Sulien |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Rashdi, Azza |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Shukri, Intisar |e verfasserin |4 aut | |
| 700 | 1 | |a Al Ghafri, Thamra S |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Hashmi, Fatma |e verfasserin |4 aut | |
| 700 | 1 | |a Al Jassasi, Saeed Mussalam |e verfasserin |4 aut | |
| 700 | 1 | |a Alshaqsi, Nasser |e verfasserin |4 aut | |
| 700 | 1 | |a Mitra, Nilanjan |e verfasserin |4 aut | |
| 700 | 1 | |a Al Aamry, Humaid Suhail |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Parag |e verfasserin |4 aut | |
| 700 | 1 | |a Al Marbouai, Hanan Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Al Araimi, Amany Hamed |e verfasserin |4 aut | |
| 700 | 1 | |a Kair, Ismail Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Al Manji, Asim Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Almallak, Ahmed Said |e verfasserin |4 aut | |
| 700 | 1 | |a Al Alawi, Fatma Khamis |e verfasserin |4 aut | |
| 700 | 1 | |a Vaidya, Vidyanand |e verfasserin |4 aut | |
| 700 | 1 | |a Muqeetullah, Muhammad |e verfasserin |4 aut | |
| 700 | 1 | |a Alrashdi, Hanan |e verfasserin |4 aut | |
| 700 | 1 | |a Al Jamoudi, Saud Said Nassir |e verfasserin |4 aut | |
| 700 | 1 | |a Alshaqsi, Asila |e verfasserin |4 aut | |
| 700 | 1 | |a Al Sharji, Abdullah |e verfasserin |4 aut | |
| 700 | 1 | |a Al Shukeiri, Hamida |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Abri, Badr |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Rawahi, Sulaiman |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Lamki, Said H |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Manji, Abdulla |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Jardani, Amina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 112(2021) vom: 03. Nov., Seite 269-277 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2021 |g day:03 |g month:11 |g pages:269-277 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2021.09.062 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2021 |b 03 |c 11 |h 269-277 | ||